Obesity

ACC 26: SURPASS-CVOT - Tirzepatide vs Dulaglutide in T2D

Steven E Nissen

Watch time: 4m 47s

Broadcast

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
e-SPACE CRM 2026 – Day Two

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
e-SPACE CRM 2026 – Day One

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Metabolic Factors Now Key Drivers of Heart Failure

Radcliffe Cardiology

Emily Morris, Oliver J Rider

Read time: 19m 30s
HFpEF-ABA Score Outperforms NT-proBNP in Trial Enrichment

Radcliffe Cardiology

Waist-to-Height Ratio Outperforms BMI in HFpEF Risk

Radcliffe CVRM

BMI Affects NT-proBNP Risk Stratification in HFpEF

Radcliffe Cardiology

AHA 2025: The TIRZSEMA-CVOT Study

Nils Krüger

Watch time: 5m 49s

Mohammed El-Sheikh, Nora Olsen El Caidi, Aginsha Kandiah, et al

Read time: 24m 35s

Nir Uriel

Watch time: 34m 39s (5 videos)
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s

Andrew JS Coats, Stefan Anker

Fausto J Pinto, John Spertus, , et al

Watch time: 2s (19 videos)
EP 105: The Year 2023 in Review with Dr Sukh Nijjer

Ankur Kalra, Sukhjinder Nijjer,

Listen time: 1h 5m 20s
EP 54: 5 Trials that will change your practice: Review of ESC 21 with Dr Purvi Parwani

Ankur Kalra, Purvi Parwani,

Listen time: 1h 17s

Joost Daemen, Nicolas M Van Mieghem

Giulio Balestrieri, Raul Limonta, Enrico Ponti, et al

Read time: 18m 10s

Emily Morris, Oliver J Rider

Read time: 19m 30s
ACC 26: SURPASS-CVOT - Tirzepatide vs Dulaglutide in T2D

Steven E Nissen

Watch time: 4m 47s

Vijay Chopra, Deepak L Bhatt, George L Bakris, et al

Stefan Anker, Giuseppe Rosano, Javier de Juan Bagudá, et al

Watch time: 15h 45m 20s (18 videos)
AHA 2025: The TIRZSEMA-CVOT Study

Nils Krüger

Watch time: 5m 49s

Nikhilesh Srinivasan, Nagesh Gullapalli, Kevin S Shah

Read time: 17m 16s

About

The high prevalence and increasing incidence of obesity and associated cardiovascular risk emphasises the need to focus on obesity reduction in this high-risk population.

Metabolic syndrome (MetS) is the coexistence of obesity-related cardiovascular risk factors including hypertension, diabetes and dyslipidaemia. MetS is a precursor for atherosclerosis, including premature coronary artery disease, and cardiovascular mortality.
 

Media

AHA 23: 3 Trials That Will Change My Practice

Dipti Itchhaporia

Watch time: 7m 20s

Stefan Anker, Giuseppe Rosano, Javier de Juan Bagudá, et al

Watch time: 15h 45m 20s (18 videos)
ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial

Harriette Van Spall, Mikhail Kosiborod

Watch time: 13m 24s
ECO 23: Impact of Obesity on Heart Failure Outcomes

Laura Meems

Watch time: 7m 7s

Fausto J Pinto, John Spertus, , et al

Watch time: 2s (19 videos)

Broadcast

Heart Failure

Prevention & Chronic Conditions
e-SPACE CRM 2023 – Day Two

Stefan Anker, Javed Butler, Antonio Ceriello , et al

Broadcast

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
e-SPACE CRM 2023 – Day One

Stefan Anker, Javed Butler, Antonio Ceriello , et al

Andrew JS Coats, Stefan Anker

Media

Broadcast

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
e-SPACE CRM 2026 – Day Two

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
e-SPACE CRM 2026 – Day One

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

ACC 26: SURPASS-CVOT - Tirzepatide vs Dulaglutide in T2D

Steven E Nissen

Watch time: 4m 47s
AHA 2025: The TIRZSEMA-CVOT Study

Nils Krüger

Watch time: 5m 49s

Nir Uriel

Watch time: 34m 39s (5 videos)
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure

Camilla Andersen

Watch time: 6m 28s
Obesity in Focus: Implications for Heart Failure, Kidney Disease, and Pharmacology

Chim C Lang, Bianca Rocca, Samira Bell, et al

Watch time: 14m 14s
Managing Obesity in HF: 2025 ACC Scientific Statement

Michelle Kittleson

Watch time: 8m 5s
Obesity, Nutrition & Mortality in Acute Heart Failure

Mohammed El-Sheikh

Watch time: 6m 34s
ESC HF 25: The PRAISE-HFrEF Study

Varun Sundaram

Watch time: 4m 10s

Jasper J Brugts

Watch time: 2m 59s (15 videos)

Articles

Left Ventricular Remodelling: A Problem in Search of Solutions

Dennis V Cokkinos

,

Christos Belogianneas

,

Citation:

European Cardiology Review 2016;11(1):29–35

DOI:

https://doi.org/10.15420/ecr.2015:9:3
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Downloads: Downloads 30
  • Citations: 37

What is Takotsubo (Stress) Cardiomyopathy?

Abhiram Prasad

,

Citation:

European Cardiology Review 2015;10(1):6–8

DOI:

https://doi.org/10.15420/ecr.2015.10.01.6
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Downloads: Downloads 11
  • Citations: 4

SGLT2 Inhibitors and HF Prevention

Muhammad Shahzeb Khan

,

Javed Butler

,

Published:

04 November 2019

Citation:

Cardiac Failure Review 2019;5(3):169–72.

DOI:

https://doi.org/10.15420/cfr.2019.06.R1
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Downloads: Downloads 51
  • Citations: 1